Running away from side effects: physical exercise as a complementary intervention for breast cancer patients.
, Martín M Abstract The number of breast cancer survivors increases every year, thanks to the development of new treatments and screening techniques. However, patients present with numerous side effects that may affect their quality of life. Exercise has been demonstrated to reduce some of these side effects, but in spite of this, few breast cancer patients know and follow the exercise recommendations needed to remain healthy. In this review, we describe the different breast cancer treatments and the related side effects and implications of exercise in relation to these. We propose that exercise could be an...
Source: Clinical Breast Cancer - June 4, 2014 Category: Cancer & Oncology Authors: Casla S, Hojman P, Márquez-Rodas I, López-Tarruella S, Jerez Y, Barakat R, Martín M Tags: Clin Transl Oncol Source Type: research

Soy foods, isoflavones, and the health of postmenopausal women.
Abstract Over the past 2 decades, soy foods have been the subject of a vast amount of research, primarily because they are uniquely rich sources of isoflavones. Isoflavones are classified as both phytoestrogens and selective estrogen receptor modulators. The phytoestrogenic effects of isoflavones have led some to view soy foods and isoflavone supplements as alternatives to conventional hormone therapy. However, clinical research shows that isoflavones and estrogen exert differing effects on a variety of health outcomes. Nevertheless, there is substantial evidence that soy foods have the potential to address severa...
Source: Clinical Breast Cancer - June 4, 2014 Category: Cancer & Oncology Authors: Messina M Tags: Am J Clin Nutr Source Type: research

Breast cancer: Post-mastectomy radiotherapy reduces recurrence and mortality.
PMID: 24889766 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2014 Category: Cancer & Oncology Authors: Orecchia R Tags: Nat Rev Clin Oncol Source Type: research

Factors perceived to influence exercise adherence in women with breast cancer participating in an exercise programme during adjuvant chemotherapy: a focus group study.
CONCLUSION: Adherence to exercise in women with breast cancer is challenged by internal and external conditions and may be improved by attention to the impact of treatment side effects and by supporting patient self-efficacy towards changing health behaviour. RELEVANCE TO CLINICAL PRACTICE: Nurses should be aware that exercise adherence could be a challenge among women with breast cancer. They should help identify obstacles to exercise for women and ways to overcome them, as well as support them in their beliefs that they are capable of changing their health behaviour. PMID: 24890796 [PubMed - as supplied by publ...
Source: Clinical Breast Cancer - June 3, 2014 Category: Cancer & Oncology Authors: Husebø AM, Karlsen B, Allan H, Søreide JA, Bru E Tags: J Clin Nurs Source Type: research

Test of Mindfulness and Hope Components in a Psychological Intervention for Women With Cancer Recurrence.
Conclusions: This treatment was feasible to deliver and was acceptable to patients. The trial serves as preliminary evidence for a multi-component intervention tailored to treat difficulties specific to recurrent cancer. The blending of the components was novel as well as theoretically and practically consistent. A gap in the literature is addressed, providing directions for testing interventions designed for patients coping with the continuing stressors and challenges of cancer recurrence. (PsycINFO Database Record (c) 2014 APA, all rights reserved). PMID: 24884347 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Thornton LM, Cheavens JS, Heitzmann CA, Dorfman CS, Wu SM, Andersen BL Tags: J Consult Clin Psychol Source Type: research

Past, Present, and Future Challenges in Breast Cancer Treatment.
PMID: 24888802 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC Tags: J Clin Oncol Source Type: research

Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database.
Abstract PURPOSE: To analyze factors that predict the use of trimodality treatment (chemotherapy, surgery, and radiation therapy [RT]) and evaluate the impact that trimodality treatment use has on survival for patients with inflammatory breast cancer (IBC). METHODS: Using the National Cancer Data Base, patients who underwent surgical treatment of nonmetastatic IBC from 1998 to 2010 were identified. We collected demographic, tumor, and treatment data and analyzed treatment and survival trends over time. Logistic regression and Cox proportional hazard models were used to examine factors predicting treatment and...
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G Tags: J Clin Oncol Source Type: research

Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
PMID: 24888812 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Arce-Salinas C, Riesco-Martinez MC, Hanna W, Bedard P, Warner E Tags: J Clin Oncol Source Type: research

Barriers to Immediate Breast Reconstruction in the Canadian Universal Health Care System.
Abstract PURPOSE: To describe the population-based rates of immediate breast reconstruction (IBR) for all women undergoing mastectomy for treatment or prophylaxis of breast cancer in the past decade, and to evaluate geographic, institutional, and patient factors that influence use in the publically funded Canadian health care system. METHODS: This population-based retrospective cohort study used administrative data that included 28,176 women who underwent mastectomy (25,141 mastectomy alone and 3,035 IBR) between April 1, 2002, and March 31, 2012, in Ontario, Canada. We evaluated factors associated with IBR b...
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Zhong T, Fernandes KA, Saskin R, Sutradhar R, Platt J, Beber BA, Novak CB, McCready DR, Hofer SO, Irish JC, Baxter NN Tags: J Clin Oncol Source Type: research

Distant Invasive Breast Cancer Recurrence Risk in Human Epidermal Growth Factor Receptor 2-Positive T1a and T1b Node-Negative Localized Breast Cancer Diagnosed From 2000 to 2006: A Cohort From an Integrated Health Care Delivery System.
CONCLUSION: The distant IR risk of T1a HER2-positive breast cancer appears quite low. The distant IR risk in T1b patients, particularly those with 1.0-cm tumors, is higher. Potential risk differences for T1a and T1b, including the 1.0-cm tumors, should be considered when making treatment decisions. PMID: 24888815 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Fehrenbacher L, Capra AM, Quesenberry CP, Fulton R, Shiraz P, Habel LA Tags: J Clin Oncol Source Type: research

Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study.
CONCLUSION: Women with T1a,b tumors have an excellent prognosis without chemotherapy. Size and tumor subtype may identify patients in whom the rate of recurrence justifies consideration of chemotherapy. These patients represent an optimal group for evaluating less toxic adjuvant regimens to maintain efficacy while minimizing short- and long-term risks. PMID: 24888816 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU Tags: J Clin Oncol Source Type: research

Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500.
Abstract PURPOSE: Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcome of overall survival (OS). PATIENTS AND METHODS: Patients with MBC who did not have increased CTCs at baseline remained on initial therapy until progression (arm A). Patients with initially increased CTCs that decreased after 21 days of therapy remained on initial ...
Source: Clinical Breast Cancer - June 2, 2014 Category: Cancer & Oncology Authors: Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF Tags: J Clin Oncol Source Type: research

Cancer treatment and survivorship statistics, 2014.
Abstract The number of cancer survivors continues to increase due to the aging and growth of the population and improvements in early detection and treatment. In order for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborated to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) program registries. In addition, current treatment patterns for the most common cancer types are described based on information in the National Cancer Data Base and the SEER and SE...
Source: Clinical Breast Cancer - June 1, 2014 Category: Cancer & Oncology Authors: DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A Tags: CA Cancer J Clin Source Type: research

Five-year Relative Survival Rate of Breast Cancer in the USA, Europe and Japan.
PMID: 24864272 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 28, 2014 Category: Cancer & Oncology Authors: Katanoda K, Matsuda T Tags: Jpn J Clin Oncol Source Type: research

Systemic treatment of HER2-positive metastatic breast cancer: A systematic review.
CONCLUSION: This review provides a strong evidence base for current clinical practice with a discussion of treatment in the Australian setting. PMID: 24797445 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 8, 2014 Category: Cancer & Oncology Authors: Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R Tags: Asia Pac J Clin Oncol Source Type: research

Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives.
Abstract Improvements in the treatment of metastatic HER2-positive breast cancer constitute one of the great advances in breast cancer medicine of the last generation. From being a highly aggressive fatal condition, the use of anti-HER2-targeted therapies, in particular trastuzumab, has led to significant improvements in disease outcomes. There are reports of increasing numbers of patients alive and well more than 5 years from diagnosis of metastatic disease. Nevertheless, there remain many complex and clinically difficult scenarios where there is little in the way of randomized evidence or published guidelines to...
Source: Clinical Breast Cancer - May 8, 2014 Category: Cancer & Oncology Authors: De Boer R, Beith J, Chirgwin J, Chua S, Colosimo M, Francis P, Green M, Pittman K, White M, Wilcken N, Zdenkowski N, Bell R Tags: Asia Pac J Clin Oncol Source Type: research

Proteomics for breast cancer urine biomarkers.
Abstract Although the survival of breast cancer (BC) patients has increased over the last two decades due to improved screening programs and postoperative adjuvant systemic therapies, many patients die from metastatic relapse. Current biomarkers used in the clinic are not useful for the early detection of BC, or monitoring its progression, and have limited value in predicting response to treatment. The development of proteomic techniques has sparked new searches for novel protein markers for many diseases including BC. Proteomic techniques allow for a high-throughput analysis of samples with the visualization and ...
Source: Clinical Breast Cancer - May 8, 2014 Category: Cancer & Oncology Authors: Beretov J, Wasinger VC, Graham PH, Millar EK, Kearsley JH, Li Y Tags: Adv Clin Chem Source Type: research

Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls.
CONCLUSION: This meta-analysis provides evidence for the association between the MDM2 rs 2279744 polymorphism and breast cancer susceptibility. The results suggest that the MDM2 rs 2279744 polymorphism plays an important role in breast cancer, especially in Asians. PMID: 24790452 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 8, 2014 Category: Cancer & Oncology Authors: Gao J, Kang AJ, Lin S, Dai ZJ, Zhang SQ, Liu D, Zhao Y, Yang PT, Wang M, Wang XJ Tags: Ther Clin Risk Manag Source Type: research

Pleomorphic lobular carcinoma of the male breast with axillary lymph node involvement: a case report and review of literature.
CONCLUSIONS: Although invasive lobular carcinomas comprise 12% of all female breast cancers, they are very rare in males due to lack of acini and lobules in the normal male breast. Pleomorphic lobular carcinoma, an aggressive variant of ILC is even rarer in males. Chronic consumption of ethanol by our patient may have resulted in some degree of hepatic impairment with resultant hyperestrogenism. This in theory may have been the cause of his gynaecomastia, resultant breast cancer and is a plausible explanation for development of the invasive lobular subtype in a male. The prognosis and clinicopatholocial features of pleomor...
Source: Clinical Breast Cancer - May 8, 2014 Category: Cancer & Oncology Authors: Zahir MN, Minhas K, Shabbir-Moosajee M Tags: BMC Clin Pathol Source Type: research

General supplement use, subsequent use and cancer risk in the UK Women's Cohort Study.
Conclusions:There was evidence that general supplement use was associated with increased smoking-related cancer risk, but there was no evidence of associations with total, colorectal and breast cancers.European Journal of Clinical Nutrition advance online publication, 7 May 2014; doi:10.1038/ejcn.2014.85. PMID: 24801368 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 7, 2014 Category: Cancer & Oncology Authors: Hutchinson J, Burley VJ, Greenwood DC, Cade JE Tags: Eur J Clin Nutr Source Type: research

In Vitro Chemoresponse Assay Based on the Intrinsic Subtypes in Breast Cancer.
CONCLUSIONS: Our findings suggest that in vitro chemoresponse assays for breast tumors could effectively reflect the tumor response to chemotherapies observed in neoadjuvant settings. PMID: 24803548 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 6, 2014 Category: Cancer & Oncology Authors: Gwe Ahn S, Ah Lee S, Woo Lee H, Min Lee H, Jeong J Tags: Jpn J Clin Oncol Source Type: research

The Microenvironment Matters: Estrogen Deficiency Fuels Cancer Bone Metastases.
Abstract Factors released during osteoclastic bone resorption enhance disseminated breast cancer cell progression by stimulating invasiveness, growth, and a bone-resorptive phenotype in cancer cells. Postmenopausal bone loss may accelerate progression of breast cancer growth in bone, explaining the anticancer benefit of the bone-specific antiresorptive agent zoledronic acid in the postmenopausal setting. Clin Cancer Res; 20(11); 1-3. ©2014 AACR. PMID: 24803577 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 6, 2014 Category: Cancer & Oncology Authors: Wright LE, Guise TA Tags: Clin Cancer Res Source Type: research

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Abstract PURPOSE: In breast cancer, the TP53 gene is frequently mutated and the mutations have been associated with poor prognosis. The prognostic impact of the different types of TP53 mutations across the different molecular subtypes is still poorly understood. Here, we characterize the spectrum and prognostic significance of TP53 mutations with respect to the PAM50 subtypes and Integrative Clusters (IC). Experimental design: TP53 mutation status was obtained for 1420 tumor samples from the METABRIC cohort by sequencing all coding exons using the Sanger method. RESULTS: TP53 mutations were found in 28.3% of ...
Source: Clinical Breast Cancer - May 6, 2014 Category: Cancer & Oncology Authors: Silwal-Pandit L, Moen Vollan HK, Chin SF, Rueda OM, McKinney SE, Osako T, Quigley D, Kristensen VN, Aparicio S, Borresen-Dale AL, Caldas C, Langerod A Tags: Clin Cancer Res Source Type: research

Estradiol affects extracellular leptin:adiponectin ratio in human breast tissue in vivo.
Abstract Context: Exposure to sex steroids is associated with increased breast cancer risk, and adipokines leptin and adiponectin have been implicated in cancer progression. However, it is not known whether sex steroids affect adipokine secretion in breast tissue. Objective: To elucidate the role of estrogen and tamoxifen on adipokine release in normal human breast tissue and breast cancer. Design, participants, and methods: Microdialysis sampling was used to collect extracellular in vivo leptin and adiponectin from normal human breast tissue in premenopausal healthy volunteers during the menstrual cycle and in po...
Source: Clinical Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: Morad V, Abrahamsson A, Dabrosin C Tags: J Clin Endocrinol Metab Source Type: research

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Abstract PURPOSE: To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. METHODS: The American Society of Clinical Oncology convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts and conducted a systematic literature review from January 2009 to October 2012. Outcomes of interest included overall survival, progression-free survival (PFS), and adverse events. RESULTS: A total of 16 trials met the systematic review c...
Source: Clinical Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP Tags: J Clin Oncol Source Type: research

Pain in Cancer Survivors.
This article focuses on patients with a history of cancer who are beyond the acute diagnosis and treatment phase and on common treatment-related pain etiologies. The benefits and harms of the various pharmacologic and nonpharmacologic options for pain management in this setting are reviewed. PMID: 24799477 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl N, Oeffinger KC, Paice JA, Stubblefield MD, Syrjala KL Tags: J Clin Oncol Source Type: research

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04.
Roh MS, Yothers G, Wolmark N Abstract PURPOSE: The optimal chemotherapy regimen administered concurrently with preoperative radiation therapy (RT) for patients with rectal cancer is unknown. National Surgical Adjuvant Breast and Bowel Project trial R-04 compared four chemotherapy regimens administered concomitantly with RT. PATIENTS AND METHODS: Patients with clinical stage II or III rectal cancer who were undergoing preoperative RT (45 Gy in 25 fractions over 5 weeks plus a boost of 5.4 Gy to 10.8 Gy in three to six daily fractions) were randomly assigned to one of the following chemotherapy regimens: conti...
Source: Clinical Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Wozniak TF Tags: J Clin Oncol Source Type: research

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline.
Abstract PURPOSE: To provide formal expert consensus-based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. METHODS: The American Society of Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts and conducted a systematic review of the literature. When that failed to yield sufficiently strong quality evidence, the Expert Panel undertook a formal expert consensus-based process to produce these re...
Source: Clinical Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU Tags: J Clin Oncol Source Type: research

HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients.
CONCLUSIONS: Better knowledge of human epidermal growth factor receptor 2 mutation status will help us to choose personalized molecular targeted therapy for use in human epidermal growth factor receptor 2-negative Japanese breast cancer patients. PMID: 24803549 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, Sato S, Takahashi S, Fujii Y, Toyama T Tags: Jpn J Clin Oncol Source Type: research

Bleomycin electrochemotherapy in elderly metastatic breast cancer patients: clinical outcome and management considerations.
Abstract PURPOSE: To evaluate the efficacy and toxicity of electrochemotherapy (ECT) in elderly metastatic breast cancer (BC) patients. METHODS: Retrospective analysis of 55 patients with superficial metastases who underwent ECT according to the European Standard Operative Procedures of electrochemotherapy. Treatment schedule consisted of intravenous or intratumoral bleomycin followed by locally delivered electric pulses. Statistical comparisons were performed between two groups: the patients aged
Source: Clinical Breast Cancer - May 3, 2014 Category: Cancer & Oncology Authors: Campana LG, Galuppo S, Valpione S, Brunello A, Ghiotto C, Ongaro A, Rossi CR Tags: J Cancer Res Clin Oncol Source Type: research

Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma.
CONCLUSIONS: We conclude that the aberrant expression of CD227, especially cytoplasm staining could be predictive for tumor aggressiveness, lymph node metastasis, poorer outcome of patients with breast cancers. And CD227 could promote the invasion ability of breast cancer cells, suggesting a potential role of CD227 as an oncogene in breast carcinoma. PMID: 24788565 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Wang YW, Shi DB, Liu YM, Sun YL, Chen X, Xiang S, Fu Q, Wei JM, Gao P Tags: J Cancer Res Clin Oncol Source Type: research

Second primary malignancies in patients with neuroendocrine tumors.
CONCLUSIONS: The percentage of patients with SPMs in the ATNEA Registry is similar to those reported in other series. In our registry, patients with functional NETs and local/locoregional tumors have higher probability of SPMs. The low number of patients, selection bias and other etiologic factors of SPMs may have influenced our results. PMID: 24788817 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Reina JJ, Serrano R, Codes M, Jiménez E, Bolaños M, Gonzalez E, Sevilla I Tags: Clin Transl Oncol Source Type: research

Screening Mammography Benefit Controversies: Sorting the Evidence.
Abstract Numerous clinical studies have confirmed that screening women age 40 years and older reduces breast cancer mortality by 30% to 50%. Several factors including faster breast cancer growth rates and lower breast cancer incidence among younger women, as well as shorter life expectancy and more comorbid conditions among older women, should also be considered in screening guidelines. Annual screening beginning at age 40 years and continuing with no upper age limit, as long as a woman has a life expectancy of at least 5 years and no significant comorbid conditions, is currently recommended. PMID: 24792...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Feig SA Tags: Radiol Clin North Am Source Type: research

BI-RADS Update.
This article summarizes the changes and updates that have been made to BI-RADS. The goal of the revised edition continues to be the same: to improve clarification in image interpretation, maintain reporting standardization, and simplify the monitoring of outcomes. The new BI-RADS also introduces new terminology to provide a more universal lexicon across all 3 imaging modalities. PMID: 24792650 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Mercado CL Tags: Radiol Clin North Am Source Type: research

Clinical Implementation of Digital Breast Tomosynthesis.
This article reviews the recent clinical data supporting digital breast tomosynthesis implementation, the basics of digital breast tomosynthesis image interpretation using case-based illustrations, and potential issues to consider as this new technology is integrated into daily clinical use. PMID: 24792652 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Conant EF Tags: Radiol Clin North Am Source Type: research

High-quality Breast Ultrasonography.
Abstract Ultrasonography is an important modality that is frequently used in all aspects of breast imaging, including breast cancer screening, the evaluation of palpable abnormalities, further characterization of lesions seen mammographically, and for determining the method of percutaneous biopsy. Understanding the basic technical aspects of ultrasonography equipment is critical to ensure high breast ultrasonography image quality. PMID: 24792653 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Sung JS Tags: Radiol Clin North Am Source Type: research

Update on Screening Breast Ultrasonography.
This article includes current recommendations for screening breast ultrasonography, a review of the literature, a discussion of problems associated with the implementation of screening breast ultrasonography, and a brief discussion of the political and economic factors influencing the use of screening breast ultrasonography. PMID: 24792654 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Merry GM, Mendelson EB Tags: Radiol Clin North Am Source Type: research

Automated Whole Breast Ultrasound.
Abstract Bilateral whole breast (screening) ultrasound has been well established in multiple single- and multi-institution published studies as a valuable adjunct to mammography screening for early detection of breast cancer. However, implementation of screening breast ultrasound programs has been limited and has met with resistance because of the number of potential false positives generated by ultrasound screening, and the lack of available personnel to perform the examination. Automated breast ultrasound, which has recently been approved by the US Food and Drug Administration for use in whole-breast ultrasound ...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Kaplan SS Tags: Radiol Clin North Am Source Type: research

High-Quality Breast MRI.
This article discusses the equipment and pulse sequences needed to achieve high-quality breast MRI and summarizes requirements of the ACR Breast MRI Accreditation Program. PMID: 24792656 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Hendrick RE Tags: Radiol Clin North Am Source Type: research

Approach to Breast Magnetic Resonance Imaging Interpretation.
This article reviews a systematic and organized approach to breast MR imaging interpretation. PMID: 24792657 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Palestrant S, Comstock CE, Moy L Tags: Radiol Clin North Am Source Type: research

Breast Magnetic Resonance Imaging: Management of an Enhancing Focus.
This article reviews published studies in order to develop a strategy for the management of enhancing foci identified on breast MR imaging. PMID: 24792658 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Ha R, Comstock CE Tags: Radiol Clin North Am Source Type: research

MR Evaluation of Breast Implants.
This article describes the rationale and indications for breast implant-related magnetic resonance (MR) imaging, alone or in combination with breast cancer-related MR imaging. Basic silicone chemistry, implant styles, and normal appearances of breast implants are described. The various presentations of breast implant rupture are described, and a 4-point staging scheme for intracapsular rupture is reviewed. Finally, a discussion of what the reviewing physician needs to know is presented, both before breast implant MR examinations are requested and afterward, when results are reported. PMID: 24792659 [PubMed - as suppli...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Middleton MS Tags: Radiol Clin North Am Source Type: research

Contrast-Enhanced Digital Mammography.
Abstract Mammography is the only technology documented to reduce breast cancer mortality. Its sensitivity, however, is 75% to 80% at best and reduced to 30% to 50% in women with dense breasts. MR imaging is a sensitive modality for the detection of breast cancer but cannot be used in all patients. Its sensitivity is due in large part to its ability to detect enhancement of tumor vascularity so cancers can be detected before a mass is present. Contrast-enhanced dual-energy mammography uses the same capability of vascular enhancement and has been demonstrated to be more sensitive than routine mammography. PMID:...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Jochelson M Tags: Radiol Clin North Am Source Type: research

Second malignancies after breast cancer: The impact of adjuvant therapy.
Abstract Second malignant neoplasms (SMNs) are potentially life-threatening late sequelae of the adjuvant therapy for breast cancer (BC). The increased risk of SMNs is associated with adjuvant chemotherapy (development of secondary acute myeloid leukemia and myelodysplastic syndrome) and hormonal therapy (risk of uterine cancer secondary to tamoxifen treatment). Previous studies have demonstrated an increased risk of SMNs associated with alkylating agents, topoisomerase-II inhibitors, granulocyte-stimulating factors and estrogen receptor modulators. Furthermore, analytical investigations have demonstrated that BC ...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Dong C, Chen L Tags: Mol Clin Oncol Source Type: research

Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects.
In this study, DNA samples were obtained from 24 breast cancer patients (mean age, 35±10 years) with a positive family history and from 71 age-matched healthy controls. Informed consent was obtained from all the subjects. Sequence-targeted BRCA1 and BRCA2 libraries were prepared using the TruSeq Custom Amplicon method and sequenced on the Illumina MiSeq system. A wide range of variants were identified in the BRCA1 and BRCA2 genes. Two pathological/presumably pathological variants were detected in the breast cancer patient group: a mutation in BRCA2 at the chromosomal (chr) position chr13:32890665, which affected the...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Balabanski L, Antov G, Dimova I, Ivanov S, Nacheva M, Gavrilov I, Nesheva D, Rukova B, Hadjidekova S, Malinov M, Toncheva D Tags: Mol Clin Oncol Source Type: research

Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer.
Abstract The present study aimed to determine the toxicity and efficacy of 4 courses of anthracyclines-taxane (AT) chemotherapy followed by radiation therapy (XRT) concurrent with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in surgically resected axillary node-positive (N+) breast cancer. A total of 200 women with N+ breast cancer were treated with adriamycin and docetaxel followed by XRT concurrent with six courses of CMF. Two courses of dose-dense chemotherapy with ifosfamide, carboplatin and etoposide, supported by pegfilgrastim, were administered to patients with>5 histologically confirmed axill...
Source: Clinical Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: Recchia F, Candeloro G, Cesta A, DI Staso M, Bonfili P, Gravina GL, DI Cesare E, Necozione S, Rea S Tags: Mol Clin Oncol Source Type: research

Low ER+ Breast Cancer: Is This a Distinct Group?
Conclusions The low ER+/HER2- cases have morphologic features and a response to the chemotherapy rate that are more similar to triple-negative tumors than the usual type of ER+ tumors. PMID: 24713741 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 11, 2014 Category: Cancer & Oncology Authors: Gloyeske NC, Dabbs DJ, Bhargava R Tags: Am J Clin Pathol Source Type: research

High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
CONCLUSION: To date, this is the largest study on Egyptian ALL patients for this SNP. This study shows that there is no effect of ABCG2 421C>A on plasma concentrations of HD-MTX. Replacing candidate gene association studies with genome-wide studies of HD-MTX is now mandatory and is part of our research blueprint. PMID: 24718721 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 10, 2014 Category: Cancer & Oncology Authors: El Mesallamy HO, Rashed WM, Hamdy NM, Hamdy N Tags: J Cancer Res Clin Oncol Source Type: research

Expression of RABEX-5 and its clinical significance in prostate cancer.
This study investigated the expression of RABEX-5 in prostate cancer by real time quantitative polymerase chain reaction and evaluated its association with clinicopathological variables, including prostate cancer patient prognosis. METHODS: A total of 180 patients with primary prostate cancer treated by radical prostatectomy were enrolled. Real time quantitative polymerase chain reaction was utilized to investigate mRNA expression level of RABEX-5 in 180 paired prostate cancer/adjacent non-cancerous tissues. RABEX-5 mRNA expression was divided into high expression group and low expression group and correlations betwee...
Source: Clinical Breast Cancer - April 9, 2014 Category: Cancer & Oncology Authors: Zhang H, Cheng S, Wang A, Ma H, Yao B, Qi C, Liu R, Qi S, Xu Y Tags: J Exp Clin Cancer Res Source Type: research

Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
Abstract Risk-reducing salpingo-oophorectomy for reducing future cancer risk in women with hereditary breast and ovarian cancer syndrome is rarely performed in Japan; therefore, the cancer preventive effect of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancer syndrome among the Japanese population remains unclear. Here, we report the first case of serous tubal intraepithelial carcinoma identified through a risk-reducing salpingo-oophorectomy in a Japanese woman with hereditary breast and ovarian cancer syndrome and who had a deleterious germline mutation of E1214X in BRCA1, but not a BRC...
Source: Clinical Breast Cancer - April 9, 2014 Category: Cancer & Oncology Authors: Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M Tags: Jpn J Clin Oncol Source Type: research